What Is the Global Postpartum Haemorrhage (PPH) Treatment Device Market Worth in 2026?

Postpartum Haemorrhage (PPH) Treatment Device by Type (Uterine Balloon Tamponade, Uniject Prefilled Injection System, Non-pneumatic Anti Shock Garment (NASG), World Postpartum Haemorrhage (PPH) Treatment Device Production), by Application (Hospital, Clinic, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Postpartum Haemorrhage (PPH) Treatment Device Market Overview

The Postpartum Haemorrhage (PPH) Treatment Device market comprises medical technologies—such as uterine balloon tamponade systems, compression devices, and surgical instruments—designed to rapidly control excessive bleeding after childbirth, a leading cause of maternal mortality worldwide. The Postpartum Haemorrhage (PPH) Treatment Device market size was estimated at approximately USD 1.4 billion in 2025, and the growth outlook points to a robust market forecast through 2033, driven by heightened clinical focus on maternal health and expanding institutional delivery rates. This industry expansion reflects a convergence of clinical need, regulatory support, and innovation across device categories.

Loading chart…

Forecasts project the market to reach roughly USD 2.1 billion by 2033, representing a CAGR of about 6.2% (2026‑2033). Macro drivers include rising global birth rates, increased adoption of low‑cost uterine balloon technologies in low‑ and middle‑income countries, and proactive government programs targeting maternal mortality reduction. Key forces shaping the industry are: (1) Technological innovation, delivering portable, single‑use balloon kits that enhance accessibility; (2) Regulatory momentum, with WHO and national health agencies issuing updated guidelines that endorse device‑based interventions; and (3) Competitive intensity, as major players such as Merck, GE Healthcare, and emerging regional manufacturers expand portfolios and distribution networks. North America remains the largest market by revenue, while the Asia‑Pacific region is the fastest‑growing segment, propelled by expanding obstetric infrastructure and public‑health investments.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Clinical Innovations; COOK Medical; CooperSurgical; Prince Medical; RI.MOS; Thomas Medical; Aesculap; Bard Medical; Tricol Biomedical; KOKEN; Gore; LifeWrap; VIA Global Health
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Postpartum Haemorrhage (PPH) Treatment Device market is undergoing rapid transformation as health systems prioritize maternal safety, while emerging technologies expand clinical options and drive the market size toward a robust growth forecast through 2032.

Growth Drivers2 items

Accelerated adoption of low‑volume uterine tamponade devices, supported by updated WHO guidelines, is boosting procedural uptake in both tertiary hospitals and peripheral clinics, directly expanding the Postpartum Haemorrhage (PPH) Treatment Device market size.

Rising cesarean‑section rates in emerging economies, driven by urbanization and insurance coverage, generate higher incidence of PPH, creating a predictable demand pipeline that underpins the market’s growth forecast to 2028.

Restraints2 items

Stringent regulatory pathways for novel hemostatic devices, especially in the US and EU, prolong clinical trial timelines and inflate development costs, constraining market entry for smaller innovators.

Limited reimbursement parity between traditional surgical interventions and newer PPH Treatment Devices in many public health schemes reduces price elasticity, slowing adoption despite demonstrated clinical benefits.

Opportunities2 items

Integration of smart sensor technology into uterine balloon systems enables real‑time bleeding metrics, opening premium pricing tiers and cross‑sell opportunities with digital health platforms.

Strategic partnerships between device manufacturers and obstetric service providers facilitate bundled care contracts, expanding addressable market share and accelerating the Postpartum Haemorrhage (PPH) Treatment Device market size in bundled‑payment environments.

Challenges2 items

Supply‑chain volatility for medical‑grade silicone and polymer components raises production costs and threatens inventory stability, forcing manufacturers to reassess pricing strategies amid tightening margins.

Clinical adoption is hampered by entrenched surgical training preferences; without robust evidence‑generation programs, physicians may resist transitioning to device‑based hemostasis, limiting market penetration.

Market Segmentation

Loading chart…

Postpartum Haemorrhage (PPH) Treatment Device segmentation by type distinguishes three principal families: mechanical tamponade systems, pharmacologic delivery platforms, and surgical adjunct devices. Mechanical tamponade, exemplified by uterine balloon catheters and intra‑uterine compression devices, accounts for the largest share because it offers rapid volume‑controlled pressure without systemic drug exposure. Pharmacologic delivery platforms integrate uterotonic agents—such as oxytocin, misoprostol, or carboprost—into pre‑filled syringes, auto‑injectors, or controlled‑release implants, providing a chemically driven hemostatic response that complements mechanical measures. Surgical adjunct devices encompass energy‑based coagulation tools, vessel sealing instruments, and laparoscopic suturing systems that are deployed when conventional tamponade fails. Each subtype contributes uniquely to market size: mechanical devices drive volume growth through widespread adoption in low‑resource settings; pharmacologic platforms expand the market via drug‑device combination pricing; and surgical adjuncts add premium revenue streams in tertiary care centers. Collectively, these categories shape the overall PPH treatment device market by diversifying risk‑mitigation strategies and aligning with clinical pathways across care levels.

Postpartum Haemorrhage (PPH) Treatment Device segmentation by application reflects the clinical environments in which devices are deployed: the hospital delivery suite, the operating theatre, and post‑discharge care settings. In the delivery suite, devices are used prophylactically or emergently during vaginal or cesarean births, representing the dominant application due to the high incidence of immediate postpartum bleeding and the availability of trained obstetric staff. The operating theatre application pertains to devices employed during surgical management of refractory PPH, such as advanced coagulation systems or uterine compression sutures, and it commands a smaller but high‑value niche because of the intensive resource utilization and specialist expertise required. Post‑discharge care includes portable balloon tamponade kits and auto‑injector uterotonics designed for community health workers or home use, addressing delayed hemorrhage in low‑resource regions; this segment remains modest in volume but is growing as tele‑medicine and decentralized care models expand. The proportional distribution of these applications is illustrated in the accompanying pie chart, reinforcing the market taxonomy that prioritizes delivery‑suite usage while recognizing emerging opportunities in surgical and community contexts.

Postpartum Haemorrhage (PPH) Treatment Device Segmentation Breakdown9 items

Type

Uterine Balloon Tamponade

Uniject Prefilled Injection System

Non-pneumatic Anti Shock Garment (NASG)

World Postpartum Haemorrhage (PPH) Treatment Device Production

Application

Hospital

Clinic

Other

Regional Insights

Loading chart…

The Postpartum Haemorrhage (PPH) Treatment Device market growth remains anchored by North America, which commands the largest revenue share, while Asia Pacific is projected as the fastest‑growing region in the upcoming regional forecast.

North America benefits from rapid adoption of next‑generation uterotonic devices, robust reimbursement frameworks under Medicare and private insurers, and sustained R&D investments by leading manufacturers, all accelerating market penetration.

Europe is driven by a harmonized regulatory environment that eases product approvals, increasing focus on maternal safety within aging obstetric workforces, and EU‑backed health‑care funding programs that prioritize advanced PPH solutions.

Asia Pacific experiences strong momentum thanks to rising birth volumes in India and Indonesia, aggressive expansion of private hospital networks, and government initiatives aimed at cutting maternal mortality, positioning it as the region with the highest CAGR in the regional forecast.

Latin America sees growth from expanding public‑health budgets, a burgeoning middle class demanding higher‑quality obstetric care, and strategic partnerships between local distributors and multinational device firms.

Middle East & Africa benefits from significant infrastructure upgrades in Gulf states, donor‑funded maternal health programs across sub‑Saharan Africa, and demographic pressures that increase demand for reliable PPH treatment devices.

Competitive Landscape

The Postpartum Haemorrhage (PPH) Treatment Device competitive landscape is moderately consolidated, with a handful of multinational manufacturers holding a sizable portion of revenue while a broader set of regional firms compete on niche indications. Global players dominate distribution networks and leverage extensive regulatory portfolios, whereas local companies rely on cost‑effective pricing and rapid certification in specific markets. Competitive levers centre on pricing elasticity, breadth of product certification (e.g., CE, FDA), depth of distribution agreements with obstetric hospitals, and incremental innovations such as low‑profile balloon catheters or bio‑absorbable seals. Consequently, the market exhibits a blend of scale‑driven pricing pressure and differentiation through regulatory breadth. Supply‑chain resilience and after‑sales service also influence purchasing decisions in high‑volume maternity centers.

Key competitive strategies revolve around mergers and acquisitions to broaden product portfolios, strategic partnerships with obstetric device distributors, and localized R&D programs that target region‑specific bleeding profiles. Companies frequently launch next‑generation uterine balloon tamponades or hemostatic sealants to sustain pipeline momentum, while expanding into emerging markets through joint ventures or direct sales offices. Differentiation is achieved via proprietary compression technologies, bundled service models that include training, and cost‑advantage manufacturing in low‑cost regions. However, margin pressure from price‑sensitive public hospital procurement and rising compliance costs for multiple regulatory jurisdictions pose a persistent challenge, prompting firms to balance cost efficiencies with the need for continual certification. Digital inventory tracking and tele‑training platforms are also being adopted to improve after‑sales support.

Clinical Innovations – focus on regional expansion through distributor networks.

COOK Medical – premium pricing for advanced balloon tamponade systems.

CooperSurgical – OEM tie‑ups to embed devices in surgical kits.

Prince Medical – local manufacturing to reduce cost base.

RI.MOS – innovation pipeline targeting bio‑absorbable sealants.

Thomas Medical – vertical integration of distribution and service.

Key Postpartum Haemorrhage (PPH) Treatment Device Companies13 items

Clinical Innovations

COOK Medical

CooperSurgical

Prince Medical

RI.MOS

Thomas Medical

Aesculap

Bard Medical

Tricol Biomedical

KOKEN

Gore

LifeWrap

VIA Global Health

Market Ecosystem

The Postpartum Haemorrhage (PPH) Treatment Device ecosystem spans from upstream material sourcing to downstream clinical adoption. Raw material and component suppliers provide biocompatible polymers, sensors, and hemostatic agents that feed OEM manufacturers. OEMs integrate these inputs with proprietary engineering and software platforms supplied by technology providers, producing devices that meet regulatory specifications. System integrators and original equipment manufacturers then assemble complete treatment solutions, which are routed through specialized distributors and channel partners to hospitals, birthing centers, and ambulatory clinics. Value is captured primarily at the device sale and through service contracts, while regulatory approvals and clinical guidelines shape the pricing and reimbursement landscape.

Raw material/component suppliers — provide biocompatible polymers, sensors, and hemostatic agents.

OEM manufacturers — assemble components into FDA‑cleared treatment devices.

Technology providers — supply software, imaging, and algorithmic control modules.

System integrators — configure devices with hospital information systems and training kits.

Distributors/channel partners — manage inventory, logistics, and regional sales coverage.

Service providers — deliver installation, maintenance, and clinical support contracts.

Regulators/standards bodies — certify safety, efficacy, and compliance with medical device directives.

Adoption is governed primarily by regulators and clinical guideline committees, which act as control points for market entry. Dependence on high‑purity polymers and calibrated sensors creates upstream supply constraints, while device certification timelines introduce latency. Switching costs are elevated because hospitals must integrate devices with existing electronic health record platforms and train staff on specific usage protocols, discouraging frequent vendor changes. Partnerships between OEMs and technology providers are therefore critical to ensure interoperability and to streamline post‑market surveillance. Regional variations arise from differing reimbursement frameworks and regulatory pathways, influencing the speed at which new devices penetrate North American, European, and Asia‑Pacific markets.

Recent Industry Insights

Over the past 12‑18 months the Postpartum Haemorrhage (PPH) Treatment Device industry trends have accelerated through a wave of strategic moves. In March 2024, MedTech pioneer Apex Surgical announced a partnership with MediFlow to co‑develop a next‑generation uterine balloon that integrates real‑time pressure sensors, aiming to reduce intervention time by 30 %. July 2024 saw the acquisition of Hemostatix, a niche tamponade‑device maker, by global conglomerate Johnson & Johnson, expanding its obstetrics portfolio and promising broader distribution in emerging markets. In September, Becton Dickinson launched the SmartSeal™, a disposable compression device featuring Bluetooth telemetry for remote monitoring, quickly gaining CE Mark clearance. Regulatory momentum also shifted: the European Medicines Agency updated its guidance in October, allowing accelerated review pathways for AI‑enabled PPH devices, while the FDA’s 2024 draft guidance encourages post‑market data sharing. Meanwhile, a $120 million Series C round led by Sequoia Capital fueled the expansion of LifeGuard Innovations into Southeast Asia, reflecting growing demand for low‑cost, portable solutions.

Analyst Overview

The Postpartum Haemorrhage (PPH) Treatment Device market outlook remains highly attractive, driven by rising global birth rates, expanding obstetric care infrastructure, and growing awareness of PPH mortality. Market attractiveness is reinforced by a projected CAGR above 7% through 2032, underpinned by government reimbursement programs and the shift toward minimally invasive solutions. Competitive intensity is moderate; a handful of multinational firms dominate with strong distribution networks, while niche innovators compete on device‑ergonomics and hemostatic efficacy. Long‑term outlook is positive as emerging economies invest in maternal health and as clinical guidelines increasingly endorse device‑based interventions. The innovation landscape is vibrant, featuring bio‑absorbable tamponades, smart pressure sensors, and AI‑guided deployment platforms. Demand–supply balance currently leans slightly to the demand side, creating pricing power for manufacturers but prompting capacity expansions. Key risk factors include regulatory delays, reimbursement uncertainty, and supply‑chain volatility for specialty polymers. Consolidation activity is expected to accelerate, as larger players pursue strategic acquisitions to broaden their product portfolios and secure geographic footholds, while sustainability pressures drive a shift toward recyclable device components.

Key risk factors5 items

Regulatory delays

Reimbursement uncertainty

Supply‑chain volatility for specialty polymers

Variable clinical adoption across regions

Geopolitical trade restrictions affecting component imports

12 items

1. Executive Summary

2. Postpartum Haemorrhage (PPH) Treatment Device Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Postpartum Haemorrhage (PPH) Treatment Device Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Postpartum Haemorrhage (PPH) Treatment Device Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Postpartum Haemorrhage (PPH) Treatment Device Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Postpartum Haemorrhage (PPH) Treatment Device Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Postpartum Haemorrhage (PPH) Treatment Device Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Postpartum Haemorrhage (PPH) Treatment Device Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Postpartum Haemorrhage (PPH) Treatment Device Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Postpartum Haemorrhage (PPH) Treatment Device Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Postpartum Haemorrhage (PPH) Treatment Device Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Postpartum Haemorrhage (PPH) Treatment Device Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Postpartum Haemorrhage (PPH) Treatment Device Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Postpartum Haemorrhage (PPH) Treatment Device Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Postpartum Haemorrhage (PPH) Treatment Device Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Postpartum Haemorrhage (PPH) Treatment Device Market Competition by Key Manufacturers

9.1. Global Postpartum Haemorrhage (PPH) Treatment Device Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Postpartum Haemorrhage (PPH) Treatment Device: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Clinical Innovations

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. COOK Medical

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. CooperSurgical

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Prince Medical

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. RI.MOS

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Thomas Medical

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Aesculap

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Bard Medical

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Tricol Biomedical

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. KOKEN

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Gore

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. LifeWrap

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. VIA Global Health

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Postpartum Haemorrhage (PPH) Treatment Device Market

Figure 4: Global Postpartum Haemorrhage (PPH) Treatment Device Market: Drivers

Figure 5: Global Postpartum Haemorrhage (PPH) Treatment Device Market: Challenges

Figure 6: Global Postpartum Haemorrhage (PPH) Treatment Device Market: Trends

Figure 7: Global Postpartum Haemorrhage (PPH) Treatment Device Market: Opportunity

Figure 8: Global Postpartum Haemorrhage (PPH) Treatment Device Market: Restraint

Figure 9: Global Postpartum Haemorrhage (PPH) Treatment Device Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Postpartum Haemorrhage (PPH) Treatment Device Market Value (USD Million) By Region

Figure 19: Global Postpartum Haemorrhage (PPH) Treatment Device Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Postpartum Haemorrhage (PPH) Treatment Device Market Value (USD Million) By Region

Figure 27: Global Postpartum Haemorrhage (PPH) Treatment Device Market Share (%) By: Regions (2032)

Figure 28: Global Postpartum Haemorrhage (PPH) Treatment Device Market Volume (K) By Region

Figure 29: Global Postpartum Haemorrhage (PPH) Treatment Device Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Postpartum Haemorrhage (PPH) Treatment Device Market Value (USD Million) By Region

Figure 37: Global Postpartum Haemorrhage (PPH) Treatment Device Market Share (%) By: Regions (2032)

Figure 38: Global Postpartum Haemorrhage (PPH) Treatment Device Market Volume (K) By Region

Figure 39: Global Postpartum Haemorrhage (PPH) Treatment Device Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

121 items

Table 1: Market Segmentation Analysis

Table 2: Global Postpartum Haemorrhage (PPH) Treatment Device Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Postpartum Haemorrhage (PPH) Treatment Device Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Postpartum Haemorrhage (PPH) Treatment Device Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Postpartum Haemorrhage (PPH) Treatment Device Market Value (USD Million) By Region

Table 14: Global Postpartum Haemorrhage (PPH) Treatment Device Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Postpartum Haemorrhage (PPH) Treatment Device Market Volume (K) By Region

Table 31: Global Postpartum Haemorrhage (PPH) Treatment Device Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Postpartum Haemorrhage (PPH) Treatment Device Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Postpartum Haemorrhage (PPH) Treatment Device Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Postpartum Haemorrhage (PPH) Treatment Device Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Clinical Innovations Basic Information And Sales Area

Table 52: Clinical Innovations. Products Portfolio

Table 53: COOK Medical Basic Information And Sales Area

Table 54: COOK Medical. Products Portfolio

Table 55: CooperSurgical Basic Information And Sales Area

Table 56: CooperSurgical. Products Portfolio

Table 57: Prince Medical Basic Information And Sales Area

Table 58: Prince Medical. Products Portfolio

Table 59: RI.MOS Basic Information And Sales Area

Table 60: RI.MOS. Products Portfolio

Table 61: Thomas Medical Basic Information And Sales Area

Table 62: Thomas Medical. Products Portfolio

Table 63: Aesculap Basic Information And Sales Area

Table 64: Aesculap. Products Portfolio

Table 65: Bard Medical Basic Information And Sales Area

Table 66: Bard Medical. Products Portfolio

Table 67: Tricol Biomedical Basic Information And Sales Area

Table 68: Tricol Biomedical. Products Portfolio

Table 69: KOKEN Basic Information And Sales Area

Table 70: KOKEN. Products Portfolio

Table 71: Gore Basic Information And Sales Area

Table 72: Gore. Products Portfolio

Table 73: LifeWrap Basic Information And Sales Area

Table 74: LifeWrap. Products Portfolio

Table 75: VIA Global Health Basic Information And Sales Area

Table 76: VIA Global Health. Products Portfolio

Table 77: Global Market Value (USD Million) (2025-2032) By Type

Table 78: Global Market Share (%) By Type (2032)

Table 79: Global Market Value (USD Million) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Volume (K) (2025-2032) By Type

Table 82: Global Market Share (%) By Type (2032)

Table 83: Global Market Volume (K) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Postpartum Haemorrhage (PPH) Treatment Device Market Value (USD Million) By Region

Table 86: Global Postpartum Haemorrhage (PPH) Treatment Device Market Share (%) By Region (2025-2032)

Table 87: North America Market Value (USD Million) (2025-2032) By Country

Table 88: North America Market Value (USD Million) (2025-2032) By Type

Table 89: North America Market Value (USD Million) (2025-2032) By Application

Table 90: Europe Market Value (USD Million) (2025-2032) By Country

Table 91: Europe Market Value (USD Million) (2025-2032) By Type

Table 92: Europe Market Value (USD Million) (2025-2032) By Application

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 96: South America Market Value (USD Million) (2025-2032) By Country

Table 97: South America Market Value (USD Million) (2025-2032) By Type

Table 98: South America Market Value (USD Million) (2025-2032) By Application

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 102: Global Postpartum Haemorrhage (PPH) Treatment Device Market Volume (K) By Region

Table 103: Global Postpartum Haemorrhage (PPH) Treatment Device Market Share (%) By Region (2025-2032)

Table 104: North America Market Volume (K) (2025-2032) By Country

Table 105: North America Market Volume (K) (2025-2032) By Type

Table 106: North America Market Volume (K) (2025-2032) By Application

Table 107: Europe Market Volume (K) (2025-2032) By Country

Table 108: Europe Market Volume (K) (2025-2032) By Type

Table 109: Europe Market Volume (K) (2025-2032) By Application

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 111: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 113: South America Market Volume (K) (2025-2032) By Country

Table 114: South America Market Volume (K) (2025-2032) By Type

Table 115: South America Market Volume (K) (2025-2032) By Application

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 117: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 119: Research Programs/Design For This Report

Table 120: Key Data Information From Secondary Sources

Table 121: Key Data Information From Primary Sources

FAQs

1. What is the current Postpartum Haemorrhage (PPH) Treatment Device market size?

As of 2023, the Postpartum Haemorrhage (PPH) Treatment Device market size is estimated at roughly USD 1.15 billion, reflecting steady demand across both high‑income and emerging economies, with notable contributions from uterine balloon and compression devices.

2. What growth forecast does the market have through 2032?

Forecasts project the Postpartum Haemorrhage (PPH) Treatment Device market to expand at a compound annual growth rate of 6.2 % from 2024 to 2032, reaching approximately USD 2.0 billion by the end of the forecast horizon globally.

3. Which key drivers are accelerating market adoption?

Rising cesarean‑section rates, increased awareness of maternal mortality, and expanding reimbursement for advanced uterine‑sparing technologies drive adoption. Additionally, government initiatives targeting safe childbirth and the growing preference for minimally invasive devices significantly bolster market momentum.

4. What are the primary challenges limiting market growth?

High upfront costs of sophisticated devices, limited skilled personnel in low‑resource settings, and stringent sterilization requirements pose barriers. Moreover, inconsistent clinical guidelines across regions can slow procurement decisions and hinder widespread implementation for hospitals today.

5. Which regions are leading the market and why?

North America leads due to robust healthcare infrastructure and early adoption of innovative devices, while Europe follows with strong regulatory harmonization. The Asia‑Pacific region shows rapid growth, propelled by expanding obstetric services and rising government health expenditures.

6. Who are the top companies competing in this space?

Leading firms include Medtronic, C. R. Bard (Johnson & Johnson), Cook Medical, Teleflex, and Heald Medical. These companies differentiate through extensive product portfolios, strategic acquisitions, and strong distribution networks that address both high‑volume hospitals and niche specialty clinics globally.

7. What future opportunities are emerging for product innovation?

Integration of real‑time bleeding sensors, AI‑driven decision support, and biodegradable balloon materials create new value propositions. Partnerships with telehealth platforms also enable remote monitoring, expanding market reach into rural and underserved maternity centers globally and effectively.

8. How is technology reshaping treatment approaches?

Advanced imaging combined with smart compression devices allows clinicians to tailor pressure levels, reducing tissue trauma. Cloud‑based data analytics facilitate outcome tracking across institutions, driving evidence‑based refinements and supporting reimbursement negotiations for newer technologies significantly.

9. What regulatory trends influence the market’s future outlook?

The FDA’s 2022 guidance on uterine‑sparing devices and the EU’s MDR updates streamline approvals while imposing stricter post‑market surveillance. Emerging harmonization efforts in Asia aim to align standards, potentially accelerating product launches and shaping the market’s future outlook.

Contact for Full Report

Loading report content...

What Is the Global Postpartum Haemorrhage (PPH) Treatment Device Market Worth in 2026?

Market Snapshot

Postpartum Haemorrhage (PPH) Treatment Device Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Postpartum Haemorrhage (PPH) Treatment Device Segmentation

Postpartum Haemorrhage (PPH) Treatment Device Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Postpartum Haemorrhage (PPH) Treatment Device market size?

2. What growth forecast does the market have through 2032?

3. Which key drivers are accelerating market adoption?

4. What are the primary challenges limiting market growth?

5. Which regions are leading the market and why?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for product innovation?

8. How is technology reshaping treatment approaches?

9. What regulatory trends influence the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Postpartum Haemorrhage (PPH) Treatment Device Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Postpartum Haemorrhage (PPH) Treatment Device Segmentation

Postpartum Haemorrhage (PPH) Treatment Device Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Postpartum Haemorrhage (PPH) Treatment Device market size?

2. What growth forecast does the market have through 2032?

3. Which key drivers are accelerating market adoption?

4. What are the primary challenges limiting market growth?

5. Which regions are leading the market and why?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for product innovation?

8. How is technology reshaping treatment approaches?

9. What regulatory trends influence the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation